Publication:
Analysis of prognostic factors and treatment outcomes for survival in hepatocellular carcinoma patients: Single institute experience

1
0

Issued Date

2019

Resource Type

Article

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-85070620827

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 102, No.7 (2019), p.50-57

Suggested Citation

Charonpongsuntorn C., Cheanklin P., Muntham D., Chommaitree P., Muangnoi P. Analysis of prognostic factors and treatment outcomes for survival in hepatocellular carcinoma patients: Single institute experience. Journal of the Medical Association of Thailand. Vol 102, No.7 (2019), p.50-57. Retrieved from: https://hdl.handle.net/20.500.14740/5266

Title

Analysis of prognostic factors and treatment outcomes for survival in hepatocellular carcinoma patients: Single institute experience

Author(s)

Charonpongsuntorn C.
 Cheanklin P.
 Muntham D.
 Chommaitree P.
 Muangnoi P.

Abstract

Objective: Primary hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and also common in Thailand. Prognosis of HCC is very poor. Staging and clinical prognostic factors is a complex issue compared to other cancer entities. Survival depends on baseline demographic, laboratory, staging and treatment modalities. The aim of the present study was retrospectively identified prognostic factors and treatment modalities that affecting overall survival outcomes. Materials and Methods: Retrospective chart review was performed. Demographic, laboratory and radiologic finding, treatment modalities were collected. Survival outcome was estimated using Kaplan-Meier analysis. The impact of clinical factors and therapy on survival was determined by univariate and multivariate analysis. Results: A total of 99 patients with HCC were included. Median overall survival was 8.9 months. Based on Barcelona Clinical Liver Cancer (BCLC) staging, patients commonly presented at intermediated or late stage, compatible with 2/3 of HCC patients received Transarterial chemoembolization (TACE) therapy when compared with other therapies including best supportive care (BSC) was significantly improved survival (p = 0.02). Patients who had no therapy have a shorter overall survival (3.7 months). Cox-Regression univariate analysis showed younger age (equal or less than 50), abdominal pain, MELD score (more than 10), larger size of tumor (more than 5 cm.), portal vein involvement, resectability, high level of biochemistry and marker such as alkaline phosphatase (ALP), alanine aminotransferase (ALT), alpha-fetoprotein (AFP) and direct bilirubin (DB) and higher BCLC staging (B-D) were identified as clinical predictors of patient survival. Statistical analysis by multivariate showed BCLC staging, age equal or less than 50, DB more than 1 mg/dL and high ALP were significantly shortening survival. Conclusion: The present study identified that BCLC staging could predict survival in patients with HCC whose therapeutic outcomes showed better survival with RFA/PEI and TACE. Despite various therapies, all of the specific treatments had survival benefit comparing to BSC alone. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND| 2019.

Subject(s)

Alanine aminotransferase
 Alkaline phosphatase
 Alpha fetoprotein
 Aspartate aminotransferase
 Bilirubin
 Abdominal pain
 Adult
 Aged
 Article
 Biochemistry
 Cancer prognosis
 Cancer staging
 Cancer survival
 Chemoembolization
 Child Pugh score
 Electrocorticography
 Human
 Liver cell carcinoma
 Local therapy
 Major clinical study
 Medical record review
 Multimodality cancer therapy
 Overall survival
 Retrospective study
 Survival rate
 Survival time
 Treatment outcome
 Tumor volume

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/5266

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By